I think this is another good reason as to why CRC.

New Post Public Reply Private Reply Replies (2) Message Board
Riztheinvestor
900
I think this is another good reason as to why CRC.

Before people start reading I’ll save you some time if you don’t want to read much further. It appears that with CRC we are trying to get accelerated approval. Makes sense I was wondering why states approval in this indication. No phase 3? Maybe? Maybe not?

FAQ Section Below From the website.

“What clinical trials is the Company currently working on?

In order of priority, the clinical trials currently under development are:

(i) a Phase II study of leronlimab in patients with relapsed/refractory microsatellite stable colorectal cancer; and

(ii) a Phase II study exploring leronlimab and its effects on inflammation.

The oncology trial, if successful, will put the Company on track towards a commercial approval in that indication. The inflammation study is aimed at clarifying a number of past clinical observations as it relates to leronlimab.”

No guarantees but I’m betting they are aiming for approval after the trial.


I posed the question to AI. Due to the wording of the website looks like we won’t be needing a phase 3 trial if this works out in our favor.



“Yes, it is possible to get special approval for a drug after a Phase 2 trial without completing a Phase 3 trial, but this is relatively rare and typically occurs under specific circumstances. Here are some of the pathways and conditions under which this can happen:

1. Accelerated Approval
- **Criteria**: This pathway allows for earlier approval of drugs that treat serious conditions and fill an unmet medical need based on a surrogate endpoint that is reasonably likely to predict clinical benefit.
- **Conditions**: The drug must show promising results in Phase 2 trials, such as significant improvement in biomarkers or other surrogate endpoints.

2. Breakthrough Therapy Designation
- **Criteria**: This designation is given to drugs that show substantial improvement over existing therapies on one or more clinically significant endpoints.
- **Conditions**: With this designation, the FDA provides intensive guidance on the development program and can expedite the review process. This can sometimes lead to approval after Phase 2 if the results are compelling enough.

3. Emergency Use Authorization (EUA)
- **Criteria**: This is used during public health emergencies to allow the use of unapproved medical products or unapproved uses of approved products.
- **Conditions**: The drug must show sufficient evidence of safety and efficacy to address the emergency situation. This is typically seen with vaccines or treatments for outbreaks like COVID-19.

4. Conditional Approval (Europe)
- **Criteria**: Similar to accelerated approval in the US, the European Medicines Agency (EMA) can grant conditional marketing authorization for medicines that address unmet medical needs.
- **Conditions**: The authorization is based on less comprehensive data than normally required, with the understanding that the company will provide additional data post-approval.

5. Compassionate Use/Expanded Access
- **Criteria**: Patients with serious or life-threatening conditions who cannot participate in a clinical trial may be allowed access to experimental drugs.
- **Conditions**: This is not an approval but allows broader use of the drug while trials are ongoing.

Examples
- **Pembrolizumab (Keytruda)**: Received accelerated approval for certain cancers based on early clinical data showing substantial benefit.
- **Remdesivir**: Received EUA during the COVID-19 pandemic after showing promise in early trials.

Conclusion
While it is possible to receive special approval for a drug after a Phase 2 trial, it requires compelling evidence that the drug is safe and effective for treating serious conditions with unmet medical needs. Regulatory agencies like the FDA and EMA have specific pathways to expedite the approval process under these circumstances.

Maybe we have a good shot of not having to complete a phase 3?

I want to see these manuscripts!

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cracking Life Insurance Needs: John Dorsa's Insights

Updated Category News Views 119

Life Insurance: A Necessary Puzzle Life’s uncertainties have a way of putting a wrench in our plans, and nothing screams uncertainty like figuring out life insurance. But fret not! HelloNation’s got insights on this financial maze, and they’ve roped in insurance pro John Dorsa from Ridgeland to help out. Calculating Coverage Needs Forget the one-size-fits-all...

Continue Reading
Alley Cat Allies Pushes for Humane Cat Conservation Bill

Updated Category News Views 70

Time to Rethink Conservation: Save the Cats If you’re tuned into the chatter buzzing around the Cayman Islands, you know the clocks are ticking for a decision that could change the approach to handling community cats. Alley Cat Allies is waving the flag, urging the Cayman Islands Parliament to pass a bill that abandons the archaic practice of culling cats by shooting...

Continue Reading
Blueprint Strengthens Team with New Capital Markets Director

Updated Category News Views 75

Blueprint Bolsters Its Ranks Hiring Caitlin Novak as Managing Director marks a pivotal step for Blueprint Healthcare Real Estate Advisors. They aren't just swapping pawns; they're making a statement, beefing up their capital markets strategy with a heavy hitter seasoned in steering around fiscal pitfalls. Novak isn’t some rookie wet behind the ears—she's clocked more...

Continue Reading
Québecor Makes Its Move: Eye on TELUS Amid Telecom Shakeup

Updated Category News Views 133

The Offer That Shocked the Telecom Markets Just when you think you’ve figured out the lay of the land, someone throws a curveball. Québecor’s decision to take a run at TELUS is shaking up Canada’s telecom scene big time. This isn’t just another M&A whisper; it’s a roaring freight train of a proposal valued at a whopping $31 billion. And TELUS, not just sitting...

Continue Reading
SahajMobile's $25M Boost: Impact on Bangladesh Market

Updated Category News Views 128

Untapped Digital Frontier in Bangladesh There's an undeniable buzz around SahajMobile's recent $25 million credit facility, and it's one worth dissecting. This shot of capital, lined up with ALMA as part of SahajMobile’s Series A gamble, is setting the stage for a real shuffle in Bangladesh's digital landscape. Plugging into a Market Gap Ever since it hit the ground...

Continue Reading
A&G Management's Bold New Era with WPM Partnership

Updated Category News Views 152

Shaking Up Baltimore's Real Estate Scene Swapping up management partners can be a dicey game, but A&G Management seems to be pulling it off without a hitch. As of January 4, 2027, WPM Real Estate Management will take over the reins for more than 3,000 apartment homes scattered across Anne Arundel, Howard, and Baltimore counties. A new set of hands is stepping in for...

Continue Reading
BWIN Acquisition Under Scrutiny: Shareholders Alerted

Updated Category News Views 118

BWIN Shareholders in the Hot Seat Over Acquisition Ever feel like you're the last one to know when the music stops in this investing dance? Well, if you're holding shares of The Baldwin Insurance Group, Inc. (NASDAQ:BWIN), it's time to put down your coffee and tune in. Levi & Korsinsky, LLP threw a wrench in the works, launching an investigation to see if this Sequence...

Continue Reading
SANY's Bold AI Showdown at bauma CHINA 2026

Updated Category News Views 60

SANY's Future Vision: AI Agents and Robotic Machinery The construction machinery game is about to get a whole lot smarter, if SANY has anything to say about it. They're rolling out their biggest show ever at bauma CHINA 2026, and the headline act? A fresh breed of AI agents and robotic machinery that promises to revolutionize the industry. Marking its 40-year legacy, SANY...

Continue Reading
DHL Leverages Robust Growth in Resilient Supply Chains

Updated Category News Views 158

Supply Chain Resilience: A Strategic Game Changer Market volatility's got its teeth in the game, and everyone in logistics knows it. DHL Supply Chain isn't just sitting back; they're riding the wave of change, snagging a 12% revenue bump in 2026. It's not your typical headline growth, either. More like the kind of growth that gets logistics gurus eyeing those contract...

Continue Reading
First Time Homebuyer Tips for Southern Maryland Success

Updated Category News Views 94

Shaking Up First-Time Homebuyer Assumptions Ever hear that age-old nonsense about needing a fat stack of cash as a down payment before you can snag your first home? Yeah, turns out that's about as outdated as a rotary phone. Robin Cavallaro from RE/MAX Realty Group in Annapolis is setting the record straight for first-time buyers in Southern Maryland. Down Payment Myths...

Continue Reading

Top 5 Most Recently Viewed Articles

Aardvark Therapeutics Advances Obesity Treatment Research

Updated Category News Views 140

Aardvark Therapeutics Unveils New Data on Obesity Treatments Aardvark Therapeutics, Inc. (AARD) recently showcased significant insights from its metabolic obesity pipeline at the latest conference dedicated to obesity, titled ObesityWeek 2025. This presentation highlighted the promising preclinical results of their innovative drug, ARD-201, which aims to enhance glucose...

Continue Reading
ITC Holdings Corp. Welcomes Carlo Capra as New VP of Engineering

Updated Category News Views 189

ITC Holdings Corp. Names Carlo Capra as Vice President of Engineering ITC Holdings Corp. has recently announced an important leadership change with the appointment of Carlo Capra as the company's new Vice President of Engineering, effective February 26, 2026. This move follows the retirement of Joe Bennett, who has played a vital role in ITC's development during his...

Continue Reading
Safeguarding Your Rights as a WEBTOON Entertainment Shareholder

Updated Category News Views 246

Understanding Your Rights as a WEBTOON Entertainment Shareholder Shareholders are urged to take action promptly, as the time to enforce your rights may be limited. Halper Sadeh LLC, an advocacy law firm focused on shareholder rights, is exploring claims regarding potential breaches of fiduciary duties by some officers and directors of WEBTOON Entertainment Inc. (NASDAQ:...

Continue Reading
TransDigm Group Delivers Strong First Quarter Performance

Updated Category News Views 124

TransDigm Group Reports First Quarter Results for Fiscal 2025 TransDigm Group Incorporated (NYSE: TDG), recognized as a leading designer, producer, and supplier of highly engineered aircraft components, recently announced their financial outcomes for the first quarter of fiscal 2025. First Quarter Financial Highlights In this first quarter, TransDigm Group achieved...

Continue Reading
Understanding Market Movements and TEM Stock Trends

Updated Category News Views 153

Market Activity Around Tempus AI In recent trading sessions, significant bearish sentiment has emerged around Tempus AI (TEM). This shift appears to be fueled by large investors taking notable positions that raise eyebrows among retail traders seeking insights on potential market movements. The Current Trading Landscape Today, we observed unusual activity in the options...

Continue Reading